Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The company’s groundbreaking GLP-1 receptor agonists have revolutionized the management of these chronic conditions, propelling Novo Nordisk to new heights in the pharmaceutical industry.

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

The company’s groundbreaking GLP-1 receptor agonists have revolutionized the management of these chronic conditions, propelling Novo Nordisk to new heights in the pharmaceutical industry. As the ...

Novo Nordisk A/S NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...